SPACE, RF ablation combo safe and effective for lung cancer

SPACE, RF ablation combo safe and effective for lung cancer
For unresectable lung tumors, the combination of segmental pulmonary arterial chemoembolization and percutaneous radiofrequency ablation helps achieve better local tumor progression rates than radiofrequency ablation alone, according to a study published in the May issue of Radiology.

(HealthDay)—For unresectable lung tumors, the combination of segmental pulmonary arterial chemoembolization (SPACE) and percutaneous radiofrequency (RF) ablation helps achieve better local tumor progression rates than RF ablation alone, according to a study published in the May issue of Radiology.

Cosmo D. Gadaleta, M.D., from the National Cancer Research Centre Istituto Tumori Giovanni Paolo II Bari in Italy, and colleagues treated 20 nodules over 19 sessions in 17 patients with primary and metastatic lung cancer. SPACE was performed, followed by percutaneous computed tomography (CT)-guided RF ablation of 48 hours later. Enhanced CT was performed 48 hours after combination, after 30 days, and then every three months. Three months after combination therapy and then every six months, fluorine 18 fluorodeoxyglucose positron emission tomography was performed.

The researchers found that in the lung parenchyma treated with SPACE there was a wide area without ventilation seen with ventilation-lung single CT. In 3- to 5-cm-diameter tumors, the local (LTP) rate was 21 percent (three of 14 nodules), and the LTP was 0 percent (zero of six nodules) in tumors of 3 cm or smaller in diameter. In 65 percent of patients, complete response was seen at a minimum of six months of follow-up. Pneumothorax occurred in five of 19 sessions (26 percent), as did one bronchopleural fistula (one of 19; 5 percent).

"Combination therapy with RF ablation after SPACE to treat unresectable is technically feasible, safe, and effective and may represent an advantage over RF ablation alone," the authors write.

One author disclosed to Angiodynamics.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

R.E.N.A.L. nephrometry score predicts treatment efficacy

Dec 27, 2012

(HealthDay)—The R.E.N.A.L. (radius, exophytic/endophytic, nearness to collecting system or sinus, anterior/posterior and location relative to polar lines) nephrometry scoring system predicts the efficacy ...

Recommended for you

Gene test aids cancer profile

10 hours ago

The first round of chemotherapy did little to suppress Ron Bose's leukemia. The second round, with 10 times the dose, knocked the proliferating blast cells down, but only by half.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.